Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.

Bibliographic Details
Title:	Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.
Authors:	Macarulla, Teresa, Yamamoto, Noboru, Tolcher, Anthony W., Hafez, Navid, Lugowska, Iwona, Ramlau, Rodryg, Geng, Junxian, Li, Jian, Teufel, Michael, Maerten, Angela, LoRusso, Patricia
Source:	Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p487-487, 151p
Database:	Supplemental Index

More Details
ISSN:	0732183X
DOI:	10.1200/JCO.2024.42.3_suppl.487
Published in:	Journal of Clinical Oncology
Language:	English